1 / 5

Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial

OPTIC Trial. Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial. Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Stuart J. Connolly. OPTIC Trial. 412 patients receiving a St. Jude Medical dual chamber ICD,

mohawk
Download Presentation

Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OPTIC Trial Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Stuart J. Connolly

  2. OPTIC Trial 412 patients receiving a St. Jude Medical dual chamber ICD, with presence of one of the following: 1) spontaneous ventricular tachycardia (VT); or 2) left ventricular (LV) ejection fraction ≤40% with either spontaneous ventricular fibrillation (VF) or inducible VT or VF. Randomized Beta-Blocker Alone Metoprolol, Carvedolol, or Bisoprolol Beta-Blocker plus Amiodarone 800 mg load plus 200 mg/day Sotalol 160 mg/day • Endpoints (1 year): Occurrence of shock (appropriate or inappropriate) Presented at ACC Scientific Sessions 2005

  3. OPTIC Trial Any Shock at 1 Year Excluding Shocks During First 21 Days Any Shock at 1 Year p<0.0001 p<0.0001 p=0.014 p=0.055 p=0.015 p=0.0057 Beta-Blocker w/ Amiodarone Sotalol Beta-Blocker w/ Amiodarone Beta-blocker Sotalol Beta-blocker • Baseline clinical characteristics were similar between the treatment groups, with 80% of patients having had a prior MI, 29% having inducible VT or VF and 71% spontaneous VT or VF. Presented at ACC Scientific Sessions 2005

  4. OPTIC Trial Inappropriate Shocks Appropriate Shocks p=0.0055 p=0.0036 p=0.20 Beta-Blocker w/ Amiodarone Sotalol Beta-Blocker w/ Amiodarone Beta-blocker Sotalol Beta-blocker • Mean number of shocks per patient was 4.32 in the beta-blocker alone group, 0.93 in the sotalol group, and 0.51 of the amiodarone plus beta-blocker group. Adverse events were similar in the three groups. Presented at ACC Scientific Sessions 2005

  5. OPTIC Trial: Summary • Among patients receiving a dual chamber ICD for spontaneous or inducible VT or VF, sotalol therapy and amiodarone plus beta-blocker therapy were associated with reductions in shocks at 1 year compared with beta-blocker therapy alone. • The reductions in the amiodarone plus beta-blocker group were greater than the sotalol group. • The addition of amiodarone or sotalol was associated with reductions in shock without an increase in adverse events, suggesting these therapies may improve the quality of life in patients implanted with an ICD. Presented at ACC Scientific Sessions 2005

More Related